NCT01133951

Helicobacter Pylori Eradication to Prevent Gastric Cancer

Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 3,000 (actual)
• Sponsor: Jie-Jun Wang · Academic / Other
• Sex: All
• Age: 30 Years – 59 Years
• Healthy volunteers: Accepted

Summary

Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection appears to reduce the risk of gastric cancer. However, several recent controlled interventional trials by H. pylori eradication to prevent gastric cancer have yielded disappointing results. The exact effect of H.pylori eradication on prevention of gastric cancer is unclear up to now. To clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether H pylori eradication would reduce the incidence of gastric cancer in a high-risk population in China.

Conditions

• Helicobacter Infections
• Stomach Neoplasms

Interventions

Type	Name	Description
DRUG	OAC triple therapy	Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
DRUG	Placebo	Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-01-01
• Completion: 2032-05-01
• First posted: 2010-05-31
• Last updated: 2023-10-10

Locations

1 site across 1 country: China